Review Article
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
Table 2
Incidence of SPMs with lenalidomide (Len)-based therapy in selected trial cohorts based on retrospective or post hoc analyses.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aExcluding nonmelanoma skin cancers. bIncidence rate per 100 person-years at risk. cStandardized incidence ratio (i.e., ratio of observed/expected rates). dRelapsed and/or refractory multiple myeloma. eNewly diagnosed multiple myeloma. fOnly MDS/AML was reported. gClarithromycin, lenalidomide, and dexamethasone. |